First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment

Tuberculosis is known to be the biggest global health problem, causing the most deaths by a single infectious agent. Vaccine-development efforts are extremely important. This paper represents the results of the first-in-human trial of recombinant subunit tuberculosis vaccine GamTBvac in a Phase I st...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Daria V. Vasina, Denis A. Kleymenov, Victor A. Manuylov, Elena P. Mazunina, Egor Yu. Koptev, Elena A. Tukhovskaya, Arkady N. Murashev, Alexander L. Gintsburg, Vladimir A. Gushchin, Artem P. Tkachuk
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2019-11-01
Colecção:	Vaccines
Assuntos:	tuberculosis subunit vaccine bcg booster clinical trials safety and immunogenicity
Acesso em linha:	https://www.mdpi.com/2076-393X/7/4/166
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!